Certain diets, adequate supplementation and above all regular exercise, seem to be key preventive actions to maintain a good metabolic health.
Metabolic health refers to how well our body makes and processes energy. Metabolic ill health – when these processes aren’t working well – is thought to be the underlying cause of many chronic metabolic conditions including obesity and diabetes.
Chronic inflammation is strongly associated with metabolic diseases such as obesity, type 2 diabetes, and cardiovascular diseases. Excess fat, particularly visceral fat, produces inflammatory cytokines (e.g., TNF-alpha, IL-6) that promote insulin resistance and interfere with normal metabolic processes. This systemic inflammation disrupts energy balance and glucose metabolism, worsening metabolic health.
Managing these factors through a healthy lifestyle, including a nutrient-rich diet, adequate supplementation, regular exercise, and stress management, is essential for maintaining metabolic health and preventing long-term diseases associated with inflammation and oxidative stress.
CHRYSEA is developing adequate and affordable interventions to address metabolic health and reducing cardiometabolic disease risk. These nutraceuticals products have multiple cytoprotective roles, including scavenging reactive oxygen species, chelating metal ions, and activating signaling pathways that regulate cellular responses to oxidative stress and inflammation.
Blood sugar management and health is one of the most intensive areas of research, with over 2,000 human studies published on the subject each year, overwhelmingly in connection with diabetes. There is also a growing interest in the links between healthy blood sugar and mood, anxiety, depression, focus and others. These connections are increasingly discussed in mainstream and social media. Research is looking at links between blood sugar management and food components.
At the heart of the metabolic process is insulin, which has been called the “master regulator” of glucose, lipid, and protein metabolism. Centrally accumulation of body fat is associated with insulin resistance, then promoting the clustering of abdominal obesity, dyslipidemia, hyperglycemia and hypertension, as major public health challenge. Increase in prevalence of obesity has become a worldwide major health problem in adults, as well as among children and adolescents as obesity is associated with a large decrease in life expectancy. The effect of extreme obesity on mortality is greater among younger than older adults.
Weight loss drugs like glucagon-like peptide-1 (GLP-1) suppresses appetite by mimicking the hormone glucagon-like peptide-1 (GLP-1), which is released after eating. It makes people feel full, thereby resulting in people eating less and reducing their overall calorie intake. Risk benefit is always to be considered on a patient by patient and is arguable whether all users need the drug or they are just doing it off-label, for the wrong use, for recreational purposes at own-risk on a “buyer beware” type scenario, despite their high-cost.
Chrysea is pursuing the development of more bioavailable and affordable interventions aimed at improving biomarkers of glycemic control e.g. fasting glucose, HbA1c, insulin, and HOMA-IR. What does it do for you? Well, managing blood glucose levels is crucial not only for preventing pre-diabetes and diabetes but also for maintaining healthy cholesterol and triglyceride levels.